Publication
10/04/2022
Intravenous immunoglobulin prevents peripheral liver transduction of intrathecally delivered AAV vectors.
Horiuchi M, Hinderer CJ, Greig JA, Dyer C, Buza EL, Bell P, Chichester JA, Hayashi PM, Yan H, Goode T, Wilson JM
Molecular Therapy. Methods & Clinical Development
Publication
1/19/2022
Prednisolone reduces the interferon response to AAV in cynomolgus macaques and may increase liver gene expression.
Wang L, Warzecha CC, Kistner A, Chichester JA, Bell P, Buza EL, He Z, Pampena MB, Couthouis J, Sethi S, McKeever K, Betts MR, Kakkis E, Wilson JM, Wadsworth S, Sullivan BA
Molecular Therapy. Methods & Clinical Development
Publication
5/05/2021
Developing a second-generation clinical candidate AAV vector for gene therapy of familial hypercholesterolemia.
Wang L, Muthuramu I, Somanathan S, Zhang H, Bell P, He Z, Yu H, Zhu Y, Tretiakova AP, Wilson JM
Molecular Therapy. Methods & Clinical Development
Publication
2/18/2021
Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9.
Wang L, Breton C, Warzecha CC, Bell P, Yan H, He Z, White J, Zhu Y, Li M, Buza EL, Jantz D, Wilson JM
Molecular Therapy : The Journal Of The American Society Of Gene Therapy
Publication
11/11/2020
MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates.
Hordeaux J, Buza EL, Jeffrey B, Song C, Jahan T, Yuan Y, Zhu Y, Bell P, Li M, Chichester JA, Calcedo R, Wilson JM
Science Translational Medicine
Publication
9/16/2020
Adeno-associated virus serotype 1-based gene therapy for FTD caused by GRN mutations.
Hinderer C, Miller R, Dyer C, Johansson J, Bell P, Buza E, Wilson JM
Annals Of Clinical And Translational Neurology